Uses of Naltrexone
Naltrexone is FDA-approved for two primary indications: alcohol dependence and opioid use disorder (for blockade of exogenously administered opioids), and it has emerging off-label uses for chronic pain conditions. 1
FDA-Approved Indications
Alcohol Dependence
Naltrexone is approved for treating alcohol dependence as part of a comprehensive management plan. The medication reduces alcohol cravings and helps prevent relapse 2. It is available as:
- Oral formulation: 50 mg daily, or alternatively 100 mg on Mondays/Wednesdays and 150 mg on Fridays
- Extended-release injection (Vivitrol): 380 mg monthly 2
Opioid Use Disorder
Naltrexone blocks the effects of exogenously administered opioids by antagonizing mu-opioid receptors 1. This indication is most effective in highly motivated populations, such as healthcare professionals who cannot or do not wish to take continuous opioid agonist therapy 2. However, it has demonstrated limited success in less motivated patient groups 2.
Critical contraindications include:
- Patients currently receiving opioid analgesics
- Patients dependent on opioids or maintained on methadone/buprenorphine
- Patients in acute opioid withdrawal
- Anyone who fails naloxone challenge or has positive urine opioid screen 1
Special Population: Adolescents
The American Academy of Pediatrics recognizes naltrexone as a treatment option for adolescents with opioid use disorders 3. Naltrexone may be particularly appropriate for adolescents with co-occurring alcohol use disorder or those in unstable/unsupervised housing, given its limited potential for misuse or diversion 3. The extended-release formulation reduces adherence burden in this population 3.
Off-Label Uses
Low-Dose Naltrexone for Chronic Pain
At doses of 1-5 mg daily (significantly lower than the FDA-approved 50 mg dose), naltrexone demonstrates immunomodulatory and analgesic effects through different pharmacodynamic pathways 4, 5. The mechanism involves:
- Glial modulation with neuroprotective effects via microglial activation inhibition
- Toll-like receptor 4 antagonism, reducing pro-inflammatory cytokine production
- Transient opioid receptor blockade causing upregulation of endogenous opioid production (opioid rebound effect) 5
Chronic pain conditions where low-dose naltrexone shows promise:
- Fibromyalgia 4, 6
- Multiple sclerosis-related pain 4, 6
- Complex regional pain syndrome 7, 5
- Diabetic neuropathy 8, 5
- Chronic musculoskeletal pain 9
- Inflammatory bowel disease (Crohn's disease) 4, 6
Important dosing consideration: The maximally effective dose is highly idiosyncratic, ranging from 0.1 to 4.5 mg daily, with most studies using 4.5 mg 9. Dosage titration is necessary to establish individual maximally effective doses, as fixed dosing may lead to treatment failure 9.
Dermatological Conditions
At standard doses (50-100 mg daily), naltrexone is used off-label for:
- Trichotillomania
- Various types of pruritus
- Familial benign chronic pemphigus (Hailey-Hailey disease)
- Dermatomyositis
- Systemic sclerosis
- Psoriasis
- Lichen planopilaris 10
Other Emerging Uses
Safety Considerations
Monitor liver function tests at baseline and every 3-6 months, as naltrexone has been associated with hepatic injury at supratherapeutic doses 2, 1. In studies using 300 mg daily (5-fold the recommended dose), 19% of patients developed transaminase elevations 1.
Common adverse effects include:
- Difficulty sleeping, anxiety, nervousness
- Abdominal pain/cramps, nausea, vomiting
- Low energy, joint/muscle pain, headache
- Vivid dreams (particularly with low-dose naltrexone) 1, 7
Critical warning: Patients who discontinue naltrexone treatment are at increased risk of opioid overdose and death due to decreased opioid tolerance 2. Naltrexone cannot be used in patients requiring opioids for pain control, as it blocks pain relief from opioid agonists 2.
The evidence for low-dose naltrexone efficacy relies primarily on subjective measures (quality of life, self-reported pain) rather than objective outcomes 4. While safety and tolerability are well-established, larger randomized controlled trials are needed to definitively establish efficacy for specific chronic pain conditions 4, 6.